Novartis (NVS) and Blackstone's (BX) Blackstone Life Sciences said Tuesday they have signed a deal for Novartis to acquire Anthos Therapeutics for up to $3.1 billion.
Novartis will make an upfront payment of $925 million at closing, and potential additional payments of up to $2.15 billion based on the achievement of regulatory and sales milestones.
Blackstone Life Sciences and Novartis launched Anthos in 2019 with exclusive international rights from Novartis to develop, produce and commercialize abelacimab, intended to prevent stroke and systemic embolism in patients with atrial fibrillation and to prevent blood clots recurrence in cancer patients. Abelacimab is currently in phase 3 development.
The transaction is expected to close in H1 this year, the companies said.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。